• NeurogesX Inc., of San Mateo, Calif., secured a $20 million loan from Hercules Technology Growth Capital Inc. Proceeds will support commercialization of FDA-approved Qutenza (capsaicin patch) for postherpetic neuralgia and Phase II trials of liquid capsaicin drug NGX-1998. (See BioWorld Today, May 3, 2010.)